UBS Upgrades Helicos BioSciences (HLCS) to Neutral
More News related to HLCS
- Helicos BioSciences to Present at Thomas Weisel Partners Healthcare Conference 2008 September 3, 2008
- Helicos Announces Personnel Changes Aimed at Accelerating R&D
- Helicos BioSciences (HLCS) Names Lombardi as New CEO
- Steve Lombardi Named CEO of Helicos BioSciences Corporation
- Helicos BioSciences (HLCS) Reports Q2 Loss of $0.57, Misses by 1c
UBS upgrades Helicos BioSciences (Nasdaq: HLCS) from Sell to Neutral.
Helicos BioSciences Corporation is a life sciences company developing genetic analysis technologies for the research, drug discovery and clinical diagnostics markets.
Related Categories
UpgradesStocks Mentioned
+0.05Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
